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The use of pyridyl and polyether compounds as auxiliary ligands to promote metal
complexation of a series of pharmaceutical analytes by electrospray ionization (ESI) is explored
as an alternative to conventional protonation by ESI. The auxiliary ligands vary in the number
and nature of binding sites, the orientation of the binding sites with respect to each other, and
the conformational flexibility of the ligand during complexation of the metal ion. The ESI of
ternary solutions composed of a pharmaceutical substrate, a transition metal ion salt, and an
auxiliary complexation agent generate metal complexes of the type [(L–H1)MII(aux)]1, where
L is the pharmaceutical, M is either copper, nickel, or cobalt, and aux is the auxiliary ligand.
Overall, the pyridine-type ligands are more useful for the generation of ternary metal
complexes than the polyether-type ligands, which preferentially complex sodium ions and,
upon collisional activation, undergo fragmentation of the polyether skeleton in addition to the
structurally informative dissociation of the analytes. The auxiliary ligand that exhibits the best
performance is 2,29-dipyridine; its ternary metal complexes enhance the structural character-
ization of five of the pharmaceuticals by promoting a greater number of fragments relative to
the CAD patterns of the protonated substrates. (J Am Soc Mass Spectrom 1998, 9,
463–472) © 1998 American Society for Mass Spectrometry
The structural determination of compounds ofbiological relevance by mass spectrometry is anextremely active area of investigation [1], largely
because of the development of matrix-assisted laser
desorption ionization (MALDI) [2] and electrospray
ionization (ESI) [3]. In the ongoing search for new
methods to extend the applicability of mass spectrom-
etry to the structural characterization of increasingly
complex molecules, alternative ionization strategies
have been developed, many involving metal complex-
ation [4]. Although most of these studies have involved
complexation of small biological molecules with alkali
and alkaline earth metal ions [4–12], there have also
been several investigations that have used transition
metal ions because it has been shown that different
transition metal ions promote different reactions with
organic molecules [13–16]. For example, fast atom bom-
bardment (FAB) has been used to generate complexes
between peptides and transition metal ions that were
subsequently characterized by collisionally activated
dissociation (CAD) [17]. Plasma desorption mass spec-
trometry (PDMS) has also been used to generate tran-
sition metal complexes with amino acids in the gas
phase [18]. The generation of metal complexes has also
been accomplished through ion–molecule reactions in-
volving laser-desorbed metal ions [19–24].
Recently, ESI has successfully been employed to
generate gas-phase transition metal complexes of small
biomolecules [25]. Gatlin et al. reported that the ESI of
methanol:water solutions containing carboxylic acids,
Cu(II) salts, and auxiliary diimine ligands such as
2,29-dipyridine and 1,10-phenanthroline resulted in the
efficient production of complexes of the form
[(RCOO2)CuII(auxiliary ligand)]1 in the gas phase [25].
This type of ternary complex has been known to exist in
the condensed phase [26, 27]. Turecek and co-workers
have also applied the same metal complexation strategy
to the analysis of amino acids [28, 29]. Gas-phase
complexes of the type [CuII(amino acid–H1)(auxiliary
ligand)]1 were generated by the ESI of methanol–water
solutions. The amino acids were found to bind the
doubly charged copper ions by their deprotonated
carboxylate groups. The main dissociation pathway of
the ternary complexes involving the amino acids was
decarboxylation; the resulting fragment ions featured
direct coordination of the a-amino alkyl residues to
copper. MSn experiments also allowed for the differen-
tiation of isomeric amino acids such as isoleucine and
leucine. CAD of the ternary complexes from amino
acids with side chains featuring oxygen, nitrogen, and
sulfur functional groups showed decarboxylation fol-
lowed by transfer of the hydroxyl, sulfide, and disulfide
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groups to the copper atom without displacement of the
auxiliary ligand. In a related study, the ESI of 1:1
methanol:water solutions composed of a dipeptide,
CuSO4 and 2,29-dipyridine resulted in the generation of
singly and doubly charged ternary complexes [30]. The
dissociation of the singly charged complexes permitted
the identification of the amino acid sequence of the
dipeptide. Upon CAD, the doubly charged complexes
generated fragment ions that allowed both the charac-
terization of the N- and C-terminal amino acid residues
and the differentiation of residues that contained iso-
meric amino acids such as leucine and isoleucine.
We have used this method of adding 2,29-dipyridine
as an auxiliary ligand to solutions containing an analyte
of interest and a transition metal ion salt to accomplish
the structural analysis of a group of quinolone antibi-
otics [31]. For example, the ESI of methanolic solutions
produced quinolone–metal complexes of the type [(L–
H1)MII(2,29-dipyridine)]1, where L is the quinolone,
and M is either Co, Ni, or Cu. Upon collisional activa-
tion, the complexes dissociated predominantly by loss
of CO2 [31]. The CAD of the copper complexes gener-
ated more useful fragments for the structural character-
ization of the quinolones relative to the nickel and
cobalt complexes. The success of these prior studies
promoted our interest in exploring whether this metal
complexation method could be used for other classes of
pharmaceuticals and whether alternative auxiliary li-
gands might allow selective tailoring of the ionization
process and more informative fragmentation patterns.
A number of auxiliary ligand candidates, shown in
Figure 1, was chosen to examine systematically the
factors that influence the formation of ternary com-
plexes. The compounds vary in the number and nature
of binding sites, the orientation of the binding sites with
respect to each other, and the conformational flexibility
of the ligand during complex formation.
The objective of this study is to evaluate the analyt-
ical utility of the metal complexes formed with the
different auxiliary ligands relative to conventional pro-
tonation or negative ionization as a means for efficient
ionization and generation of structurally diagnostic
ions. In this study, a series of different pharmaceuticals
is used as substrates (Figure 2) in order to evaluate the
general applicability of the method. Camptothecin is an
antileukemic agent. Cephalosporin C, nalidixic acid,
tetracycline, and fusidic acid are antibacterial agents,
while cortisone, isoxicam, and indoprofen are anti-
inflammatory agents. Vincamine is a vasodilator, cro-
molyn is an anti-asthmatic agent, and lasalocid A is a
coccidiostat used for poultry. Metal complexes are
produced by ESI, and CAD is used to evaluate the
structures of the pharmaceutical-metal complexes. The
aim is to create metal complexes that produce richer
CAD patterns than the protonated analytes, thus en-
abling the construction of customized spectral libraries
for identification of an array of targeted analytes in
mixtures.
Experimental
ESI
Experiments were performed using a Finnigan MAT
Ion Trap Detector (ITD) operating in the mass-selective
instability mode with modified electronics to allow for
axial modulation. The electrospray system [32, 33] is
based on the design of the Oak Ridge National Labora-
tory ion trap group and its operation has been ex-
plained in detail elsewhere [31]. Briefly, solutions con-
taining the analyte were pumped through a 30 cm
section of Teflon™ tubing at the rate of 1–5 mL/min.
The needle tip was placed 1–2 cm from the inlet
aperture of the interface. A positive voltage of 3–4 kV
was applied to the needle for positive ion mode, and
ions were injected through a 100 mm diameter sampling
orifice in the front plate, typically maintained at 100–
120 V. Typical injection times were 100–200 ms.
CAD experiments were performed on each isolated
metal complex. Collisional activation was performed by
the application of an ac voltage of 0.3–0.4 Vp–p at the
axial frequency of motion of the ion of interest. A qz
value of 0.3 was used; activation times were typically 10
ms. The mass-selective instability mode was used to
eject the fragment ions from the trap onto an electron
multiplier for detection [34].
Solutions
The metal complexes for the electrospray experiments
were prepared by dissolving the substrate, the transi-
Figure 1. Auxiliary ligands.
464 ALVAREZ AND BRODBELT J Am Soc Mass Spectrom 1998, 9, 463–472
tion metal ion salt, and the auxiliary ligand in a suitable
solvent to achieve a concentration of about 1 3 1024 M
for all components in the mixture. For nalidixic acid,
indoprofen, cortisone, vincamine, cromolyn, lasalocid
A, and fusidic acid the solvent was methanol, whereas
tetracycline and isoxicam were dissolved in acetonitrile.
Cephalosporin C and camptothecin were dissolved in
mixtures of methanol and water, and acetonitrile and
water, respectively. For the experiments in which the
protonation of the substrates was the main focus, the
solvent used was mixed with acetic acid in a 99:1 ratio.
Reagents
Camptothecin, cobalt(II) bromide, 12-crown-4, 18-
crown-6, 2,29-dipyridine, 4,49-dipyridine, monoglyme,
nalidixic acid, nickel(II) iodide, 1,10-phenanthroline,
2,29:69,20-terpyridine, tetraglyme (Aldrich Chemical
Co., Milwaukee, WI), cephalosporin C, cortisone, cro-
molyn, lasalocid A, vincamine, fusidic acid, indoprofen,
isoxicam, tetracycline (Sigma Chemical Co., St. Louis,
MO), copper(II) sulfate pentahydrate (Spectrum Chem-
ical Mfg. Corp., Gardena, CA), reagent grade acetoni-
trile, and reagent grade methanol (EM Science, Gibbs-
town, NJ) were used as materials for this study. All
reagents were used as received.
Results
Formation and CAD of the Protonated Substrates
Prior to the metal complexation studies, an examination
of the ESI mass spectra of the analytes in acidified
solutions was undertaken. The major molecular species
observed in the ESI mass spectra obtained for the
acidified solutions are summarized in Table 1. An
example of a typical ESI mass spectrum is shown in
Figure 3 for isoxicam. The spectrum is dominated by
low mass ions and low abundances of (L1H1) and
(L1Na1), where L is isoxicam. Camptothecin, corti-
sone, cephalosporin C, vincamine, nalidixic acid, and
tetracycline protonate efficiently to form intense (L1
Figure 2. Pharmaceutical substrates.
Table 1. Molecular species from ESI
Substrate (MW) Ions (%)
Nalidixic acid (232.23) (L1H1) (100)
Indoprofen (281.32) (L1H1) (18)
(L1Na1) (82)
Isoxicam (335.33) (L1H1) (40)
(L1Na1) (39)
(L1Na112CH3CN) (21)
Tetracycline (444.43) (L1H1) (100)
Fusidic acid (516.69) (L1H11H2O) (48)
(L1Na1) (52)
Camptothecin (348.34) (L1H1) (91)
(L1Na1) (9)
Cortisone (360.46) (L1H1) (90)
(L1Na1) (10)
Cephalosporin C (415.44) (L1H1) (100)
Vincamine (354.43) (L1H1) (97)
(L1Na1) (3)
Lasalocid A (590.80) (L1H1) (6)
(L1Na1) (94)
Cromolyn (468.38) (L1H11Na11H2O) (100)
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H1) ions. The rest of the analytes protonate poorly; the
mass spectra for these substrates are dominated by the
sodium complexes. Indoprofen, fusidic acid, and isoxi-
cam apparently contain a high concentration of sodium,
probably as a result of synthetic or refining steps in
their preparation and purification. For cromolyn, isoxi-
cam, and fusidic acid, attachment of either water or
solvent molecules to the (L1Na1) complex is also
observed.
The CAD spectra of the protonated analytes are
summarized in Table 2. One example is shown in Figure
4 for protonated isoxicam. Protonated isoxicam disso-
ciates by cleavage of the carboxamide moiety or by loss
of the isoxazole ring. The major dissociation pathway
for (camptothecin1H1) is the loss of 44 u. Less domi-
nant fragmentation channels involve dissociations of
the lactone ring, which is a highly reactive portion of
the molecule that has been related to the biological
activity of this pharmaceutical [35]. Protonated nalidixic
acid dissociates predominantly by loss of water or loss
of water and 28 u [36]. Dehydration is the main frag-
mentation pathway for (vincamine1H1); another im-
portant dissociation channel involves the loss of 60 u.
This net loss of C2H4O2 can be rationalized as either the
consecutive elimination of methanol and carbon mon-
oxide or as the concerted loss of methyl formate involv-
ing the ester group present in the molecule [37]. Proto-
nated cortisone undergoes dehydration and
fragmentation along its lactone ring. The major dissoci-
ation pathway for (tetracycline1H1) is also dehydra-
tion; a less dominant dissociation pathway involves the
loss of water in conjunction with deamination [38].
Upon CAD, the (L1H1) ion from cephalosporin C
dissociates predominantly by loss of CH3COOH or loss
of CH3COOH and CO2. Two less intense fragmentation
channels are rationalized as dissociation across the
dihydrothiazine ring (loss of 274 u) and as fragmenta-
tion across the b-lactam ring followed by loss of NH3
(loss of 232 u). For indoprofen, lasalocid A, cromolyn,
and fusidic acid, the intensity of the protonated species
was not sufficient to perform CAD.
For some of the analytes (indoprofen, isoxicam,
fusidic acid, lasalocid A) that formed abundant sodium
adducts, CAD of the sodium adducts was explored.
Although the sodium adducts could be efficiently acti-
vated, no fragment ions were observed. The lack of
fragment ions was attributed to the preferential disas-
sembly of the complex and formation of sodium ions.
Because of the low mass-to-charge ratio of sodium,
these ions were not trapped. Overall, the CAD spectra
of these sodium complexes were uninformative.
Formation of Transition Metal Complexes
Because conventional protonation was not effective for
all of the analytes and because CAD of the protonated
Figure 3. Typical ESI mass spectrum.
Table 2. CAD of protonated substrates: neutral losses
Substrate (MW)
Fragments
(%)
Nalidixic acid (232.23) 218 (93)
246 (7)
Indoprofen (281.32) NAa
Isoxicam (335.33) 298 (5)
2126 (39)
2211 (56)
Tetracycline (444.43) 218 (77)
235 (23)
Fusidic acid (516.69) NA
Camptothecin (348.34) 244 (81)
272 (9)
2100 (10)
Cortisone (360.46) 218 (34)
2199 (66)
Cephalosporin C (415.44) 260 (20)
2104 (43)
2232 (12)
2274 (25)
Vincamine (354.43) 218 (78)
247 (6)
260 (6)
275 (3)
2143 (#3)
2203 (#3)
2212 (#3)
Lasalocid A (590.80) NA
Cromolyn (468.38) NA
aNot available; the intensity of the protonated substrate was not
sufficient to perform CAD.
Figure 4. CAD spectrum of (L1H1) for isoxicam.
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analytes did not always generate adequate structural
information, alternative ionization methods were con-
sidered. Negative ionization via deprotonation of the
analytes was attempted, but ongoing difficulties with
obtaining reproducible, intense negative ion signals on
a daily basis were noted. The negative ionization mode
was much more sensitive to the cleanliness of the ESI
source and interface, the interface pressure, and the
stability of the ESI spray, thus proving to be ineffective
for the diverse array of analytes in this study. Com-
plexation with transition metal ions was evaluated as
another option. The formation of metal complexes was
first attempted by electrospraying solutions containing
each pharmaceutical and a transition metal ion salt.
ESI of solutions consisting of each pharmaceutical
and Co(II)Br2 failed to generate abundant complexes of
the type (L1Co21); tetracycline was the only substrate
that generated this complex to a minor extent. All the
substrates are slightly acidic substances: fusidic acid,
indoprofen, and nalidixic acid possess carboxylic acid
groups, while tetracycline and isoxicam both feature an
enol functionality that can easily deprotonate. Presum-
ably the absence of metal complexes may stem from the
preferential formation of electroneutral complexes of
the type [CoII(L–H1)2] or [Co
II(L–2H1)].
Because metal complexes were not efficiently gener-
ated by electrospraying the simple metal/analyte solu-
tions, an auxiliary ligand was used to bind the metal ion
[28–30]. ESI of solutions composed of each pharmaceu-
tical analyte, Co(II)Br2, and each auxiliary ligand can-
didate yielded mass spectra that exhibited a variety of
ionic species. The mass spectra are summarized in Table
3. An example of a typical ESI mass spectrum for a
pharmaceutical/Co(II)Br/auxiliary ligand system is
shown in Figure 5 for isoxicam. The [(L–H1)CoII(2,29-
dipyridine)]1 complex is the dominant high mass spe-
cies, and the [Co(2,29-dipyridine)2]
21 complex is the
most intense ion in the lower mass region.
ESI of pharmaceutical/Co(II)Br/auxiliary ligand so-
lutions proves to be a successful strategy for generating
complexes of the type [(analyte–H1)CoII(auxiliary li-
gand)]1 for five of the analytes. These complexes are
analogous to the ternary complexes generated for the
quinolones [31] and to those probed by Turecek and
co-workers [28–30]. As with the quinolones, the forma-
tion of the pharmaceutical/transition metal ion com-
plex is promoted when the analyte loses an acidic
proton and forms a covalent dative bond with the metal
ion [28, 29]. The possession of an acidic site that can be
deprotonated with relative ease seems to be of para-
mount importance for the generation of this type of
ternary complex, as substrates without a sufficiently
acidic hydrogen do not generate metal complexes. The
structures of the complexes likely involve chelation or
resonance interactions, factors that were identified in
the quinolone studies [31] as being important for the
formation of stable ternary complexes.
2,29-Dipyridine was the auxiliary ligand that gener-
ated the most abundant ternary complexes with most of
the substrates. The general success of this auxiliary
ligand can be attributed to two main factors. First, the
two nitrogen binding sites are in close proximity to each
other and can undergo cooperative interactions when
complexing the metal ion. Second, the fact that there is
free rotation along the C–C bond that joins the two
pyridyl rings provides this compound with a greater
Table 3. Mass spectra of ternary solutions involving cobalta
Substrate
(MW) 2,29-Dipyridine 4,49-Dipyridine 1,10-Phenanthroline 2,29:69,20-Terpyridine
Nalidixic acid
(232.23)
(L1H1) (39) (dipy1H1) (59) (L1H1) (52) [Co(terpy)2]
21 (68)
[(L1H1)CoII(dipy)]1 (61) (L1H1–H2O) (14) [(L–H
1)CoII(phen)]1 (48) [(L–H1)CoII(terpy)]1 (32)
(L1H1) (13)
(L1Co12CH3OH)
1 (14)
Indoprofen
(281.32)
(dipy1H1) (8) (dipy1H1) (84) [Co(phen)2]
21 (42) [Co(terpy)2]
21 (93)
[Co(dipy)2]
21 (11) (L1Na1) (16) [Co(phen)3]
21 (27) (L1Na1) (3)
[Co(dipy)3(H2O)]
21 (31) [(L–H1)CoII(phen)]1 (31) [(L–H1)CoII(terpy)]1 (4)
(L1Na1) (9)
[(L–H1)CoII(dipy)]1 (41)
Isoxicam
(335.33)
[Co(dipy)2]
21 (49) (dipy1H1) (100) [Co(phen)2]
21 (57) [Co(terpy)2]
21 (89)
[Co(dipy)2(CH3CN)]
21 (9) [Co(phen)2(CH3CN)]
21 (8) (L1H1) (0.6)
[Co(dipy)3(H2O)]
21 (4) (L1Na1) (6) (L1Na1) (0.9)
[(L–H1)CoII(dipy)]1 (38) (L1H11CH3CN) (9) (L1Na
114H2O) (6)
[(L–H1)CoII(phen)]1 (20) [(L–H1)CoII(terpy)]1 (3.5)
Tetracycline
(444.43)
[Co(dipy)(H2O)]
21 (36) (dipy1H1) (100) [Co(phen)(CH3CN)2]
21 (5) [Co(terpy)2]
21 (95)
[Co(dipy)2]
21 (47) [Co(phen)2]
21 (38) [Co(terpy)]1 (4)
[Co(dipy)2]
1 (7) [Co(phen)2]
1 (57) (L1H1) (1)
[(L–H1)CoII(dipy)]1 (10)
Fusidic acid
(516.69)
[Co(dipy)3(H2O)]
21 (21) (dipy1H1) (100) [Co(phen)2]
21 (46) [Co(terpy)]21 (8)
[(L–H1)CoII(dipy)]1 (79) [Co(phen)3]
21 (5) [Co(terpy)2]
21 (92)
[Co(phen)(CH3OH)2]
21 (28)
[(L–H1)CoII(phen)]1 (21)
(Continued)
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degree of conformational flexibility to accommodate the
considerably bulkier pharmaceuticals into the complex.
This optimized complexation geometry results in ter-
nary complexes of increased stability.
4,49-Dipyridine was the only auxiliary ligand that
failed to generate ternary complexes with any of the
pharmaceuticals. The predominant ionic species in the
mass spectra for the solutions including 4,49-dipyridine
is the protonated auxiliary ligand; for isoxicam, tetra-
cycline, and fusidic acid, it is the sole product. The
inability of 4,49-dipyridine to generate ternary com-
plexes with any of the substrates is surely related to the
fact that its two nitrogen binding sites are located at
opposite sides of the molecule and do not have the
opportunity to undergo cooperative interactions during
complexation of the metal ion. This results in the
formation of a metal complex that is very unstable and
presumably disassembles into the separate compo-
nents.
The performance of 1,10-phenanthroline and 2,29:
69,20-terpyridine as auxiliary ligands falls somewhere in
between the two different dipyridines. 1,10-Phenanth-
roline generates ternary complexes with four of the
substrates, whereas 2,29:69,20-terpyridine is able to form
complexes with only three. These two auxiliary ligands
bind the metal ion so strongly that they ultimately
displace the substrate, forming abundant [Co(aux)2]
21
complexes. Similarly to 2,29-dipyridine, 1,10-phenanth-
roline possesses two nitrogen binding sites; however, it
lacks the conformational flexibility of the former as its
skeleton is locked into a rigidly planar conformation by
the presence of a third aromatic ring between the two
pyridyl rings. The binding strength of 1,10-phenanthro-
line to the metal ion is greatly enhanced, thus disfavor-
ing the competitive attachment of a more weakly bind-
ing pharmaceutical ligand. In the case of 2,29:69,20-
terpyridine, an additional nitrogen binding site further
enhances the binding affinity of the ligand for the
Table 3 (continued from previous page). Mass spectra of ternary solutions involving cobalta
Substrate
(MW) 12-crown-4 18-crown-6 Monoglyme Tetraglyme
Nalidixic acid
(232.23)
(12-c-41H1) (11) (18-c-61H1) (7) (L1H1) (78) (tetragly1H1) (2)
(12-c-41H11H2O) (8) (18-c-61H
11H2O) (70) [(L–H
1)CoIIL]1 (18) (tetragly1H11H2O) (58)
(12-c-41Na1) (4) (18-c-61Na1) (13) [(L–H1)CoII(monogly)]1 (4) (tetragly1Na1) (38)
(L1H1) (39) [(L–H1)CoII(18-c-6)]1 (10) [(L–H1)CoII(tetragly)]1 (2)
(2 3 12-c-4 1 Co)21 (8)
[(L–H1)CoIIL]1 (11)
[(L–H1)CoII(12-c-4)]1
(19)
Indoprofen
(281.32)
(12-c-41Na1) (85) (18-c-61Na1) (99) (monogly1Na1) (27) (tetragly1Na1) (100)
(2 3 12-c-41Na1) (13) [(L–H1)CoII(18-c-6)]1 (1) (L1Na1) (73)
[(L–H1)CoII(12-c-4)]1 (2)
Isoxicam
(335.33)
(12-c-41Na1) (68) (18-c-61Na1) (100) [Na1(CH3CN)] (49) (tetragly1Na
1) (99)
(2 3 12-c-41Na1) (32) (monogly1Na1) (49) (L1Na1) (0.9)
(L1Na1) (1.5) [(L–H1)CoII(tetragly)]1 (0.1)
(L1Na112CH3CN) (0.5)
Tetracycline
(444.43)
(12-c-41Na1) (81) (18-c-61H11H2O) (21) (2 3 monogly1Co1CH3CN)
21
(78)
(tetragly1H11H2O) (15)
(2 3 12-c-41Na1) (19) (18-c-61Na1) (73) (2 3 monogly1H12CH3CN)
1
(17)
(tetragly1Na1) (80)
(18-c-61H11CH3CN) (6) (L1H
1) (5) (tetragly1Na11H2O) (5)
Fusidic acid
(516.69)
(12-c-41Na1) (61) (18-c-61Co)21 (48) (monogly1Na11H2O) (71) (tetragly1Co)
21 (23)
(12-c-41Co1CH3OH)
21
(18)
(18-c-61Na1) (52) (L1Na1) (4) (tetragly1Na1) (56)
(12-c-41Co1
2CH3OH)
21 (7)
[(L–H1)CoII]1 (25) (2 3 tetragly1Co)21 (15)
[(L–H1)CoII(12-c-4)]1
(14)
[(L–H1)CoII]1 (6)
aPercent distribution in parentheses.
Key: dipy, dipyridine; phen, phenanthroline; terpy, terpyridine; 12-c-4, 12-crown-4; 18-c-6, 18-crown-6; monogly, monoglyme; tetragly, tetraglyme.
Figure 5. ESI mass spectrum of a solution of isoxicam, Co(II)Br,
and 2,29-dipyridine.
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transition metal ion relative to the binding strength of
the pharmaceutical substrate, thus leading to [Co-
(terpyridine)2]
21 complexes. The displacement of the
pharmaceuticals from the metal center is further pro-
moted by the fact that transition metal ions are bound
more strongly by nitrogen binding sites than by oxygen
binding sites.
Overall, the polyether auxiliary ligands had the
worst performance for the generation of abundant
ternary complexes with the pharmaceuticals. Out of 20
possible ternary complexes that could have been
formed, only eight were produced. Of these eight
ternary complexes, only four were sufficiently intense
to permit CAD studies. The significant decrease in their
ability to form ternary metal complexes with the phar-
maceuticals stems from the fact that the polyethers have
extremely large alkali metal binding affinities relative to
transition metal binding affinities. As mentioned ear-
lier, the pharmaceutical substrates naturally contain a
lot of sodium from either their purification or synthesis,
and even solvents and glassware possess trace quanti-
ties of alkali metal salts. The polyether ligands prefer-
entially bind the ubiquitous sodium ions, creating huge
(polyether1Na1) signals. In fact, the average intensity
of the desired ternary complexes is only 6% relative to
the (polyether1Na1) ions. This contamination problem
did not interfere with the complexation of the pyridyl-
containing ligands; none of the pyridyl-containing so-
lutions produced complexes that incorporated sodium.
Not all the pharmaceuticals pictured in Figure 2
could be analyzed successfully. This metal complex-
ation strategy was not amenable to cortisone, campto-
thecin, vincamine, cephalosporin C, cromolyn, and la-
salocid A. Several reasons may account for the failure of
these pharmaceuticals to form their respective ternary
metal complexes. It is possible that some of these
substrates do not possess a hydrogen that is sufficiently
acidic. The formation of ternary metal complexes de-
pends heavily on the presence of an acidic site in the
pharmaceutical that can undergo facile deprotonation.
For example, camptothecin, cortisone, and vincamine
possess moderately acidic hydroxyl groups but not
carboxylic acid groups. Another scenario involves the
converse of this situation. It is possible that some of
these pharmaceuticals contain more than one site that is
sufficiently acidic to deprotonate very efficiently. If this
is the case, a large population of deprotonated substrate
ions in solution could easily lead to the formation of
abundant [Co21(L–2H1)] complexes. This particular
type of ternary complex is electroneutral and thus
cannot be detected. Cephalosporin C and cromolyn
both have two carboxylic groups, and thus might fall
into this category. A third possibility involves the
formation of ternary complexes that are very unstable
and easily disassemble into their separate components.
If the most acidic site in the substrate is sterically
hindered, presumably the relatively bulky [Co(aux)]21
ion cannot approach it effectively, and the metal ion
will ultimately be unable to form a strong dative bond
with the negatively charged site. As an example, the
hydroxyl group of vincamine is relatively hindered,
and thus might suffer from this effect.
The formation of an unstable metal complex can also
occur in the absence of steric effects. If the most acidic
site in the molecule is not sterically hindered but is
located far away from any other functional group that
can undergo cooperative interactions through chelation
to assist in the binding of the metal ion, the resulting
ternary complex could be unstable. All of the pharma-
ceutical compounds in the present study were selected
because of their chelating functional groups, so this
possibility seems unlikely. A fifth possibility is that
some of the pharmaceutical compounds might have
such extremely large metal binding strengths that they
displace the auxiliary ligand from the ternary complex,
ultimately resulting in electroneutral dimers of the type
[(L–H1)2Co
21]. For example, the large metal binding
strength of lasalocid A has been well documented
[39–41], so it may form these neutral dimers. Because
all the pharmaceuticals that failed the metal complex-
ation experiments possess very complex structures, it is
likely that several of these factors are operative.
CAD of Ternary Complexes Involving Cobalt
In order to assess the analytical value of the different
auxiliary ligand candidates with respect to metal com-
plex formation and to characterize the nature of the
ternary complexes, the complexes were isolated and
subjected to collisional activation. The CAD spectrum
for the [(L–H1)CoII(2,29-dipyridine)]1 complex of isoxi-
cam is shown in Figure 6 as an example. A variety of
structurally diagnostic fragment ions are observed. The
CAD results are summarized in Table 4.
Collisional activation of the ternary complexes fre-
quently promoted new fragmentation channels that
were not observed for the protonated substrates, thus
providing characteristic fingerprints for each analyte.
For example, the [(L–H1)CoII(2,29-dipyridine)]1 com-
plex of tetracycline gives rise to an increased number of
fragments, including the losses of 18, 35, and 46 u
corresponding to the loss of water, the loss of water and
Figure 6. CAD of the [(L–H1)CoII(dipy)]1 complex from isoxi-
cam.
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ammonia, and the loss of water and CO, respectively.
For tetracycline, the CAD spectrum of the metal com-
plexes is more structurally informative than the CAD
spectrum of protonated tetracycline which predomi-
nantly showed dehydration.
The improved analytical value of the ternary metal
complexes is elegantly illustrated with the fragmenta-
tion behavior of isoxicam. As mentioned previously,
protonated isoxicam dissociates by cleavage of its car-
boxamide moiety to form only two intense fragment
ions and one minor one. The metal complex involving
2,29-dipyridine dissociates more efficiently to generate
an extensive number of fragments (Figure 6). Even
though the most intense dissociation channel is still the
cleavage of the carboxamide moiety (formation of m/z
311 by loss of 238 u), a wealth of new fragment ions
provides a definite structural fingerprint for this com-
pound and is available for use in selected ion monitor-
ing and/or pattern recognition strategies.
The applicability of metal complexation for struc-
tural characterization is underscored by the results from
the CAD experiments involving the ternary complexes
of fusidic acid and indoprofen. The structural charac-
terization of these compounds could not be accom-
plished via protonation because these compounds did
not protonate efficiently. They, on the other hand, form
ternary metal complexes more readily and more effi-
ciently. Upon collisional activation, the ternary com-
plexes involving fusidic acid dissociate by cleavage of
the ester moiety, a functionality that has been directly
related to its biological activity. For the indoprofen
metal complexes, the main fragmentation pathway is
the loss of 46 u. Thus, the generation of metal complexes
involving these pharmaceuticals allowed for the acqui-
sition of structural information that permitted their
characterization.
Relative to the CAD spectral information obtained
from the pharmaceutical/pyridyl ligand/metal com-
plexes, the CAD spectra of the polyether-containing
complexes did not prove to be as analytically useful. As
a group, they did not form abundant ternary complexes
with most of the substrates; 12-crown-4, the most useful
Table 4. CAD of [(L–H1)CoII(auxiliary ligand)]1 complexes: neutral lossesa
Substrate
(MW)
2,29-
Dipyridine
4,49-
Dipyridine
1,10-
Phenanthroline
2,29:69,20-
Terpyridine 12-crown-4 18-crown-6 Monoglyme Tetraglyme
Nalidixic acid
(232.23)
244 (100) NA 244 (97) 244 (95) 244 (6) 226 (24) NA 244 (55)
272 (3) 272 (5) 288 (7) 244 (6) 2108 (28)
2233 (87) 2132 (59) 2290 (17)
2202 (11)
Indoprofen
(281.32)
246 (100) NA 246 (100) 2280 (100) NA NA NA NA
Isoxicam
(335.33)
264 (4) NA 264 (8) 2188 (15) NA NA NA NA
2107 (3) 2152 (8) 2203 (23)
2134 (6) 2176 (12) 2238 (21)
2152 (3) 2238 (32) 2253 (10)
2162 (3) 2293 (10) 2303 (8)
2176 (4) 2303 (14) 2309 (10)
2188 (4) 2320 (16) 2336 (13)
2238 (31)
2293 (5)
2303 (6)
2309 (3)
2320 (13)
2334 (11)
2336 (4)
Tetracycline
(444.43)
218 (6) NA NA NA NA NA NA NA
235 (2)
246 (20)
264 (18)
280 (3)
298 (4)
2160 (3)
2188 (13)
2216 (5)
2276 (3)
2292 (7)
2502 (16)
Fusidic acid
(516.69)
2456 (100) NA 2456 (100) NA 2294 (20) NA NA NA
2456 (80)
aPercent distribution in parentheses.
Not available; the intensity of the metal complex was insufficient for CAD.
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auxiliary ligand, was able to generate ternary com-
plexes with only two of them. Monoglyme did not form
ternary complexes that were sufficiently abundant to be
suitable for collisional activation with any of the phar-
maceuticals, whereas both 18-crown-6 and tetraglyme
only did so with one. Most importantly, the analytical
merit of the CAD spectra generated by the few com-
plexes was minimal. For several of the ternary com-
plexes, the polyether ligands underwent dissociation of
their skeletal backbones upon collisional activation, an
occurrence that is undesirable because it clutters the
CAD spectra with noninformative fragments. For exam-
ple, the loss of 88 u from the [(L–H1)CoII(12-crown-4)]1
complex from nalidixic acid can be rationalized as loss
of CO2 from the substrate in conjunction with loss of
C2H4O from the polyether or as loss of two units of
C2H4O from the polyether portion. The loss of 132 u
from the [(L–H1)CoII(18-crown-6)]1 complex from na-
lidixic acid most likely is the loss of CO2 from the
substrate followed by two consecutive losses of C2H4O
from the ligand, or loss of three units of C2H4O from the
polyether portion, while the loss of 108 u from [(L–
H1)CoII(tetraglyme)]1 is assigned as the loss of CO2
from the substrate followed by two consecutive losses
of CH3OH from the polyether. Protonated crown ethers
are known to undergo multiple losses of C2H4O units
upon collisional activation [42], so this behavior is not
surprising for other metal complexes containing poly-
ethers. The metal complexes of the larger glymes, in
addition to losses of C2H4O units, are also known to
undergo losses of CH3OH [43]. Therefore, in addition to
sodium contamination problems, the polyether auxil-
iary ligands are afflicted by weakness in their structural
integrity, a quality that limits their applicability for this
type of metal complexation strategy.
Formation and CAD of Ternary Complexes
Involving Copper and Nickel
As mentioned previously, the use of other transition
metals might further expand the versatility of the ESI
metal complexation method. Studies with nickel and
copper ions were undertaken to evaluate the efficiency
of complex formation and the structural utility of the
resulting CAD patterns. In the ESI process, the copper
and nickel complexes are judged to be almost equally
intense as the cobalt complexes, based on spraying the
analogous copper, nickel, and cobalt solutions back-to-
back and noting the signal intensity. Thus, the use of
these three transition metals appears promising for
alternative ionization strategies.
The ternary complexes that involved 2,29-dipyridine,
the most useful auxiliary ligand, with nickel and copper
ions were isolated and subjected to collisional activa-
tion. For example, the CAD spectrum for the [(tetracy-
cline–H1)CuII(2,29-dipyridine)]1 shows only one dom-
inant fragmentation pathway (dehydration), and the
spectrum is much simpler than the one obtained for the
analogous cobalt complex. The other CAD results are
summarized in Table 5. In general, the nickel complexes
do not generate as many fragment ions as the cobalt
complexes. Furthermore, most of these dissociation
products do not offer any new information that can
provide additional structural fingerprints for the char-
acterization of the pharmaceuticals. For example, the
main dissociation pathway for nickel complexes from
nalidixic acid is loss of CO2 (44 u), in direct accord with
the results from its cobalt complexes. For three of the
analytes (nalidixic acid, indoprofen, and fusidic acid),
the copper complexes dissociate into a greater array of
fragment ions than was noted for the cobalt complexes.
Thus, initial evidence suggests that the CAD spectra can
be tailored by changing the transition metal in the
complexes.
Conclusions
The formation of ternary transition metal complexes in
conjunction with CAD in a quadrupole ion trap has
been evaluated as a new option for the analysis of
pharmaceutical compounds. Although this strategy was
not successful for every pharmaceutical compound, the
method is an easy complement to conventional proto-
nation methods and may provide a useful alternative
with a minimum of time-consuming compound-specific
developmental effort. For 5 of the 11 diverse com-
pounds in the present study, the ternary complexes
were successfully generated. The strategy significantly
improved the ionization efficiency of three of the com-
pounds (isoxicam, indoprofen, fusidic acid) relative to
protonation. The best auxiliary ligand was 2,29-dipyri-
dine; it produced the most abundant metal complexes.
Overall, the pyridyl-type ligands were more useful for
the generation of ternary metal complexes than the
polyether ligands, which were much more susceptible
to preferential complexation of sodium ions. Upon
collisional activation, the complexes containing poly-
ether ligands were also prone to undergo skeletal
fragmentation of the polyether, giving uninformative
fragmentation pathways and complicating the spectral
Table 5. CAD of [(L–H1)MII(2,29-dipyridine)]1 complexes:
neutral lossesa
Substrate (MW) [(L–H1)NiII(dipy)]1• [(L–H1)CuII(dipy)]1•
Nalidixic acid (232.23) 244 (100) 244 (66)
272 (7)
2196 (15)
2282 (12)
Indoprofen (281.32) 246 (100) 246 (72)
2280 (28)
Isoxicam (335.33) 2238 (100) 2334 (100)
Tetracycline (444.43) 218 (100) 218 (100)
Fusidic acid (516.69) 2273 (21) 260 (34)
2456 (79) 2176 (22)
2254 (44)
aPercent distribution in parentheses.
Key: dipy, 2,29-dipyridine.
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interpretation process. Based on comparative CAD ex-
periments, the ternary complexes involving 2,29-dipyri-
dine enhanced the characterization of five of the ana-
lytes by promoting a greater number of structurally
diagnostic fragmentation channels as compared to the
CAD spectra of the protonated species. For two of the
analytes, the Co(II) complexes provided the greatest
array of fragmentation pathways, but the Cu(II) com-
plexes generated the most fragmentation pathways for
the other three analytes.
Because of the relatively high rate of total failure of
the method, the strategy would not be promising for
screening diverse mixtures of drugs or other com-
pounds. The method is more useful for the analysis of
specific classes of drugs for which the method has
shown initial validity (i.e., the class of anti-inflamma-
tory compounds including isoxicam), in terms of pro-
viding richer CAD spectra or allowing ionization of
compounds that do not protonate efficiently during ESI.
In addition, the CAD spectra obtained for the ternary
metal complexes could be used to create customized
spectral libraries for subsequent routine analyses or to
allow more options for selected reaction monitoring.
Thus, overall the method shows greatest applicability to
studies involving repetitive analysis of samples contain-
ing targeted compounds, but not for confident analysis
of unknown mixtures.
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